MANNKIND CORP Direct Financing Lease, Deferred Selling Profit
MANNKIND CORP (MNKD) had Direct Financing Lease, Deferred Selling Profit of $2.08 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:DirectFinancingLeaseDeferredSellingProfit · last filed 2026-08-05
- 2026-06-30: Direct Financing Lease, Deferred Selling Profit $2.08M.
- 2026-03-31: Direct Financing Lease, Deferred Selling Profit $1.96M.
- 2025-12-31: Direct Financing Lease, Deferred Selling Profit $2.11M.
- 2025-09-30: Direct Financing Lease, Deferred Selling Profit $1.96M.
| Period end | Direct Financing Lease, Deferred Selling Profit |
|---|---|
| 2026-06-30 | $2.08M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.96M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $2.11M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.96M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.07M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.37M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $2.42M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.48M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.81M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.61M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.42M 10-K · filed 2025-02-26 |
| 2023-09-30 | $1.18M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $944.00K 10-Q · filed 2023-08-07 |
| 2023-03-31 | $851.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.30M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.34M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.42M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.19M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.38M 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.26M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.35M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $1.43M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $1.42M 10-K · filed 2022-02-24 |
| 2020-09-30 | $1.42M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $1.42M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.42M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.43M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.41M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $1.43M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $1.54M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $257.00K 10-K · filed 2020-02-25 |
| 2017-12-31 | $118.00K 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |